Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > RuBCG HUGE POTENTIAL
View:
Post by Tarbaby on Jul 11, 2024 1:44pm

RuBCG HUGE POTENTIAL

Their discovery that Rudivar combined with BCG increased the effectivness of BCG is potentially a huge game changer for bladder cancer treatment.
That alone might be worth billions..
They have so many cookies in their cookie jar..
Comment by Oilminerdeluxe on Jul 11, 2024 2:08pm
The good Lbiati could perhaps work her magic with the recent stream of PR's at her disposal. Some new updates are always welcome.
Comment by CancerSlayer on Jul 11, 2024 2:48pm
Yep...you can now add RuBCG to their list of invaluable "proprietary" formulations.  The in-vitro data suggests RuBCG has the potential to replace BCG as the stand-alone therapy/standard of care for NMIBC imo.  The beauty of its potential is found in its mechanism of action (MOA).   It turns a negatively-charged BCG, which is repelling to a negatively-charged cancer cell ...more  
Comment by plantrader on Jul 11, 2024 3:10pm
Then it's settled, Merck can buy the rights to RuBCG for $2B and then Theralase can continue with their other indications as planned. Dr Lbiati, make a few calls and gitterdun. :-P
Comment by CancerSlayer on Jul 11, 2024 3:19pm
Additionally, Rutherrin was also found to decrease the expression of PD-L1 proteins on NMIBC & GBM cancer cells, thereby allowing a better immune response & higher cancer cell kill rate.  This MOA can potentially be utilized in combination with other approved PD-L1 inhibitors (i.e. Durvalumab, Atezolizumab) in order to make these inhibitors become more effective/efficient.  You ...more  
Comment by Legit62 on Jul 11, 2024 4:15pm
Once we have BTD for bladder cancer under our belts, our worth becomes in the billions because now we know the other indications we will be going for and that we have our compound approved, we becoome a major target for big pharma, until BTD, fingers crossed,would definitely like to see in 24 but will take early 25 if FDA plays games with us
Comment by skys1 on Jul 11, 2024 4:22pm
Slayer, you've got such a great sales pitch on RuBCG, Management should send you out to make some sales calls on the Pharma world.with Dr Lbiati. You would no doubt create a frantic mad rush to be first to get in on the grounf floor of the RuBCG treatment.
Comment by skys1 on Jul 11, 2024 4:26pm
Slayer, don't laugh at my last post. I know Management will read it. No telling what could come of it.
Comment by plantrader on Jul 11, 2024 4:55pm
skys, That's an interesting and exciting idea. But seems like we'd have to assume Dr Lbiati is way ahead of us on that thought and is a qualified expert trying to sell this potential to BP already. We just need something officially positive to happen to break this stalemate or malaise. BTD, Partnership, Buyout, JV. Whatever, something to validate the years of effort by the company and its ...more  
Comment by Alamir1111 on Jul 12, 2024 8:57am
Kind of surprised, dr.Lbiati is still around, I guess she sees something that might be worth pursuing? 
Comment by plantrader on Jul 12, 2024 9:10am
Have you verified that she's still associated? She's still on their website, so that's good. Not sure how often they update the site.
Comment by Alamir1111 on Jul 12, 2024 9:30am
All public companies are required to notify shareholders if there is any changes to managment directors etc
Comment by plantrader on Jul 12, 2024 10:17am
Good, then hopefully she's out there turning over all possible stones.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250